Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

BACKGROUND: Vilobelimab, an anti-C5a monoclonal antibody, was shown to be safe in a phase 2 trial of invasively mechanically ventilated patients with COVID-19. Here, we aimed to determine whether vilobelimab in addition to standard of care improves survival outcomes in this patient population. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Vlaar, Alexander P J, Witzenrath, Martin, van Paassen, Pieter, Heunks, Leo M A, Mourvillier, Bruno, de Bruin, Sanne, Lim, Endry H T, Brouwer, Matthijs C, Tuinman, Pieter R, Saraiva, José F K, Marx, Gernot, Lobo, Suzana M, Boldo, Rodrigo, Simon-Campos, Jesus A, Cornet, Alexander D, Grebenyuk, Anastasia, Engelbrecht, Johannes M, Mukansi, Murimisi, Jorens, Philippe G, Zerbib, Robert, Rückinger, Simon, Pilz, Korinna, Guo, Renfeng, van de Beek, Diederik, Riedemann, Niels C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9451499/
https://www.ncbi.nlm.nih.gov/pubmed/36087611
http://dx.doi.org/10.1016/S2213-2600(22)00297-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9451499/
https://www.ncbi.nlm.nih.gov/pubmed/36087611
http://dx.doi.org/10.1016/S2213-2600(22)00297-1

Ejemplares similares